Onconetix, Inc. (ONCO) Stock Competitors & Peer Comparison

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, NVO has a market cap of 195B. Regarding current trading prices, ONCO is priced at $1.08, while NVO trades at $44.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas NVO's P/E ratio is 10.30. In terms of profitability, ONCO's ROE is -1.05%, compared to NVO's ROE of +0.66%. Regarding short-term risk, ONCO is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check NVO's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, VRTX has a market cap of 112.9B. Regarding current trading prices, ONCO is priced at $1.08, while VRTX trades at $452.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 26.37. In terms of profitability, ONCO's ROE is -1.05%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ONCO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check VRTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ONCO is priced at $1.08, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ONCO's ROE is -1.05%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ONCO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check VRNA's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, REGN has a market cap of 63.1B. Regarding current trading prices, ONCO is priced at $1.08, while REGN trades at $613.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 14.94. In terms of profitability, ONCO's ROE is -1.05%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ONCO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check REGN's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, ONCO is priced at $1.08, while ARGX trades at $884.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 39.71. In terms of profitability, ONCO's ROE is -1.05%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, ONCO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ARGX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ONCO is priced at $1.08, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ONCO's ROE is -1.05%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ONCO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SGEN's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ALNY has a market cap of 37.8B. Regarding current trading prices, ONCO is priced at $1.08, while ALNY trades at $286.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 70.89. In terms of profitability, ONCO's ROE is -1.05%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ONCO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ALNY's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, RVMDW has a market cap of 36.1B. Regarding current trading prices, ONCO is priced at $1.08, while RVMDW trades at $6.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas RVMDW's P/E ratio is N/A. In terms of profitability, ONCO's ROE is -1.05%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ONCO is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for ONCO.Check RVMDW's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, RVMD has a market cap of 32.7B. Regarding current trading prices, ONCO is priced at $1.08, while RVMD trades at $159.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -21.64. In terms of profitability, ONCO's ROE is -1.05%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ONCO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RVMD's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, RPRX has a market cap of 23.6B. Regarding current trading prices, ONCO is priced at $1.08, while RPRX trades at $54.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 28.88. In terms of profitability, ONCO's ROE is -1.05%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, ONCO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RPRX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, ONCO is priced at $1.08, while UTHR trades at $552.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 20.18. In terms of profitability, ONCO's ROE is -1.05%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ONCO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check UTHR's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ONCO is priced at $1.08, while BNTX trades at $91.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -15.50. In terms of profitability, ONCO's ROE is -1.05%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ONCO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BNTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, INCY has a market cap of 21.7B. Regarding current trading prices, ONCO is priced at $1.08, while INCY trades at $102.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 15.33. In terms of profitability, ONCO's ROE is -1.05%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ONCO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check INCY's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ROIV has a market cap of 21.6B. Regarding current trading prices, ONCO is priced at $1.08, while ROIV trades at $30.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -55.63. In terms of profitability, ONCO's ROE is -1.05%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ONCO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ROIV's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, INSM has a market cap of 21.2B. Regarding current trading prices, ONCO is priced at $1.08, while INSM trades at $98.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -16.99. In terms of profitability, ONCO's ROE is -1.05%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ONCO is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check INSM's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ONCO is priced at $1.08, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ONCO's ROE is -1.05%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ONCO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BGNE's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, MRNA has a market cap of 19.8B. Regarding current trading prices, ONCO is priced at $1.08, while MRNA trades at $50.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -6.13. In terms of profitability, ONCO's ROE is -1.05%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ONCO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MRNA's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ONCO is priced at $1.08, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ONCO's ROE is -1.05%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ONCO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check DNA-WT's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, NBIX has a market cap of 16.1B. Regarding current trading prices, ONCO is priced at $1.08, while NBIX trades at $157.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 24.62. In terms of profitability, ONCO's ROE is -1.05%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ONCO is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check NBIX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, GMAB has a market cap of 15.4B. Regarding current trading prices, ONCO is priced at $1.08, while GMAB trades at $24.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 19.00. In terms of profitability, ONCO's ROE is -1.05%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ONCO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check GMAB's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, ONCO is priced at $1.08, while JAZZ trades at $230.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 2096.00. In terms of profitability, ONCO's ROE is -1.05%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ONCO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check JAZZ's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, ONCO is priced at $1.08, while ASND trades at $222.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ASND's P/E ratio is 25.01. In terms of profitability, ONCO's ROE is -1.05%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ONCO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ASND's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, EXEL has a market cap of 13.4B. Regarding current trading prices, ONCO is priced at $1.08, while EXEL trades at $52.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 17.59. In terms of profitability, ONCO's ROE is -1.05%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ONCO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check EXEL's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, AXSM has a market cap of 13.1B. Regarding current trading prices, ONCO is priced at $1.08, while AXSM trades at $253.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -68.59. In terms of profitability, ONCO's ROE is -1.05%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ONCO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check AXSM's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, ONCO is priced at $1.08, while BBIO trades at $67.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -17.86. In terms of profitability, ONCO's ROE is -1.05%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ONCO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BBIO's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ONCO is priced at $1.08, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ONCO's ROE is -1.05%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ONCO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check KRTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, IONS has a market cap of 12.1B. Regarding current trading prices, ONCO is priced at $1.08, while IONS trades at $73.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -36.46. In terms of profitability, ONCO's ROE is -1.05%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ONCO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check IONS's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ONCO is priced at $1.08, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ONCO's ROE is -1.05%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ONCO is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RNAM's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, ONCO is priced at $1.08, while MDGL trades at $495.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -35.59. In terms of profitability, ONCO's ROE is -1.05%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ONCO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MDGL's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, SMMT has a market cap of 10.9B. Regarding current trading prices, ONCO is priced at $1.08, while SMMT trades at $14.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -8.81. In terms of profitability, ONCO's ROE is -1.05%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ONCO is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SMMT's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, ONCO is priced at $1.08, while BMRN trades at $55.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 40.25. In terms of profitability, ONCO's ROE is -1.05%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ONCO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BMRN's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ARWR has a market cap of 10.5B. Regarding current trading prices, ONCO is priced at $1.08, while ARWR trades at $76.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -32.83. In terms of profitability, ONCO's ROE is -1.05%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ONCO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ARWR's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ONCO is priced at $1.08, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ONCO's ROE is -1.05%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ONCO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RXDX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, KRYS has a market cap of 9.4B. Regarding current trading prices, ONCO is priced at $1.08, while KRYS trades at $323.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 42.57. In terms of profitability, ONCO's ROE is -1.05%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ONCO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check KRYS's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ONCO is priced at $1.08, while NUVL trades at $123.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -20.34. In terms of profitability, ONCO's ROE is -1.05%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ONCO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check NUVL's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CORT has a market cap of 8.9B. Regarding current trading prices, ONCO is priced at $1.08, while CORT trades at $83.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 236.89. In terms of profitability, ONCO's ROE is -1.05%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ONCO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CORT's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CYTK has a market cap of 8.7B. Regarding current trading prices, ONCO is priced at $1.08, while CYTK trades at $70.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -10.24. In terms of profitability, ONCO's ROE is -1.05%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ONCO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CYTK's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ONCO is priced at $1.08, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ONCO's ROE is -1.05%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ONCO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check IMGN's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, ONCO is priced at $1.08, while TECH trades at $55.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 77.14. In terms of profitability, ONCO's ROE is -1.05%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ONCO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TECH's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ONCO is priced at $1.08, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ONCO's ROE is -1.05%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ONCO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BPMC's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, ONCO is priced at $1.08, while HALO trades at $70.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 24.39. In terms of profitability, ONCO's ROE is -1.05%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ONCO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check HALO's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ONCO is priced at $1.08, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, ONCO's ROE is -1.05%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ONCO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CERE's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, TGTX has a market cap of 7.6B. Regarding current trading prices, ONCO is priced at $1.08, while TGTX trades at $50.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 17.31. In terms of profitability, ONCO's ROE is -1.05%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ONCO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TGTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, IBRX has a market cap of 7.4B. Regarding current trading prices, ONCO is priced at $1.08, while IBRX trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -8.35. In terms of profitability, ONCO's ROE is -1.05%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ONCO is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check IBRX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ONCO is priced at $1.08, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ONCO's ROE is -1.05%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ONCO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MTSR's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ALKS has a market cap of 7.4B. Regarding current trading prices, ONCO is priced at $1.08, while ALKS trades at $43.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 49.20. In terms of profitability, ONCO's ROE is -1.05%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ONCO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ALKS's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, KYMR has a market cap of 7.1B. Regarding current trading prices, ONCO is priced at $1.08, while KYMR trades at $86.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -24.08. In terms of profitability, ONCO's ROE is -1.05%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ONCO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check KYMR's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, PTGX has a market cap of 7.1B. Regarding current trading prices, ONCO is priced at $1.08, while PTGX trades at $111.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is -60.65. In terms of profitability, ONCO's ROE is -1.05%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ONCO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check PTGX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, ONCO is priced at $1.08, while IMVT trades at $33.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -12.14. In terms of profitability, ONCO's ROE is -1.05%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ONCO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check IMVT's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, PCVX has a market cap of 6.9B. Regarding current trading prices, ONCO is priced at $1.08, while PCVX trades at $49.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -6.89. In terms of profitability, ONCO's ROE is -1.05%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ONCO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check PCVX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ONCO is priced at $1.08, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ONCO's ROE is -1.05%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ONCO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MRUS's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ONCO is priced at $1.08, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ONCO's ROE is -1.05%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ONCO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ACLX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, LEGN has a market cap of 6.6B. Regarding current trading prices, ONCO is priced at $1.08, while LEGN trades at $35.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -25.99. In terms of profitability, ONCO's ROE is -1.05%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ONCO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check LEGN's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ONCO is priced at $1.08, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, ONCO's ROE is -1.05%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ONCO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RETA's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, LQDA has a market cap of 6.3B. Regarding current trading prices, ONCO is priced at $1.08, while LQDA trades at $70.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 419.00. In terms of profitability, ONCO's ROE is -1.05%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ONCO is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check LQDA's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ABVX has a market cap of 6.3B. Regarding current trading prices, ONCO is priced at $1.08, while ABVX trades at $102.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -18.15. In terms of profitability, ONCO's ROE is -1.05%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ONCO is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ABVX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, PTCT has a market cap of 6.2B. Regarding current trading prices, ONCO is priced at $1.08, while PTCT trades at $73.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is -29.58. In terms of profitability, ONCO's ROE is -1.05%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ONCO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check PTCT's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, ONCO is priced at $1.08, while CNTA trades at $39.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -22.31. In terms of profitability, ONCO's ROE is -1.05%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ONCO is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CNTA's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, ONCO is priced at $1.08, while RYTM trades at $92.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -28.24. In terms of profitability, ONCO's ROE is -1.05%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ONCO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RYTM's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, ONCO is priced at $1.08, while COGT trades at $33.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -15.25. In terms of profitability, ONCO's ROE is -1.05%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ONCO is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check COGT's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, PRAX has a market cap of 5.6B. Regarding current trading prices, ONCO is priced at $1.08, while PRAX trades at $265.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -19.92. In terms of profitability, ONCO's ROE is -1.05%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ONCO is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check PRAX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ONCO is priced at $1.08, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ONCO's ROE is -1.05%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ONCO is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CDTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, ONCO is priced at $1.08, while BLTE trades at $141.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -54.39. In terms of profitability, ONCO's ROE is -1.05%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, ONCO is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BLTE's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ONCO is priced at $1.08, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ONCO's ROE is -1.05%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ONCO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ABCM's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ONCO is priced at $1.08, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ONCO's ROE is -1.05%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ONCO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ISEE's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, APGE has a market cap of 5.5B. Regarding current trading prices, ONCO is priced at $1.08, while APGE trades at $87.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -20.40. In terms of profitability, ONCO's ROE is -1.05%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ONCO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check APGE's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, ONCO is priced at $1.08, while FBIOX trades at $25.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ONCO's ROE is -1.05%, compared to FBIOX's ROE of N/A. Regarding short-term risk, ONCO is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check FBIOX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, ONCO is priced at $1.08, while SRRK trades at $45.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -12.81. In terms of profitability, ONCO's ROE is -1.05%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ONCO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SRRK's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, ONCO is priced at $1.08, while CGON trades at $60.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -25.45. In terms of profitability, ONCO's ROE is -1.05%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ONCO is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CGON's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ONCO is priced at $1.08, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 38.35. In terms of profitability, ONCO's ROE is -1.05%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ONCO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check APLS's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, LGND has a market cap of 5.1B. Regarding current trading prices, ONCO is priced at $1.08, while LGND trades at $255.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 33.36. In terms of profitability, ONCO's ROE is -1.05%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ONCO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check LGND's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, ONCO is priced at $1.08, while CAI trades at $18.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CAI's P/E ratio is -6.51. In terms of profitability, ONCO's ROE is -1.05%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ONCO is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CAI's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, ONCO is priced at $1.08, while MIRM trades at $102.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -7.30. In terms of profitability, ONCO's ROE is -1.05%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ONCO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MIRM's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, SYRE has a market cap of 4.9B. Regarding current trading prices, ONCO is priced at $1.08, while SYRE trades at $83.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -38.11. In terms of profitability, ONCO's ROE is -1.05%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ONCO is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SYRE's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, ONCO is priced at $1.08, while TVTX trades at $53.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -104.08. In terms of profitability, ONCO's ROE is -1.05%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ONCO is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TVTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, ONCO is priced at $1.08, while CRSP trades at $52.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -8.07. In terms of profitability, ONCO's ROE is -1.05%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ONCO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CRSP's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ONCO is priced at $1.08, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.41. In terms of profitability, ONCO's ROE is -1.05%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ONCO is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TERN's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ONCO is priced at $1.08, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ONCO's ROE is -1.05%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ONCO is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check FOLD's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ONCO is priced at $1.08, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ONCO's ROE is -1.05%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ONCO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check AKRO's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ONCO is priced at $1.08, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ONCO's ROE is -1.05%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ONCO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ALPN's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ERAS has a market cap of 4.4B. Regarding current trading prices, ONCO is priced at $1.08, while ERAS trades at $14.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -15.11. In terms of profitability, ONCO's ROE is -1.05%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ONCO is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ERAS's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, ONCO is priced at $1.08, while CELC trades at $87.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -22.71. In terms of profitability, ONCO's ROE is -1.05%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ONCO is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CELC's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ONCO is priced at $1.08, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, ONCO's ROE is -1.05%, compared to OPT's ROE of +1.09%. Regarding short-term risk, ONCO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check OPT's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, ONCO is priced at $1.08, while XENE trades at $52.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -11.23. In terms of profitability, ONCO's ROE is -1.05%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ONCO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check XENE's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ONCO is priced at $1.08, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ONCO's ROE is -1.05%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ONCO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MRTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, MANE has a market cap of 4B. Regarding current trading prices, ONCO is priced at $1.08, while MANE trades at $95.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas MANE's P/E ratio is -36.32. In terms of profitability, ONCO's ROE is -1.05%, compared to MANE's ROE of -0.95%. Regarding short-term risk, ONCO is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MANE's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, KNSA has a market cap of 3.9B. Regarding current trading prices, ONCO is priced at $1.08, while KNSA trades at $52.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 57.02. In terms of profitability, ONCO's ROE is -1.05%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ONCO is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check KNSA's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, ONCO is priced at $1.08, while CPRX trades at $31.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 18.13. In terms of profitability, ONCO's ROE is -1.05%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ONCO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CPRX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, ONCO is priced at $1.08, while VCYT trades at $48.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 43.82. In terms of profitability, ONCO's ROE is -1.05%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, ONCO is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check VCYT's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ONCO is priced at $1.08, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ONCO's ROE is -1.05%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ONCO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RYZB's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, ONCO is priced at $1.08, while EWTX trades at $34.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -20.98. In terms of profitability, ONCO's ROE is -1.05%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ONCO is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check EWTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ONCO is priced at $1.08, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ONCO's ROE is -1.05%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ONCO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CBAY's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, ONCO is priced at $1.08, while CRNX trades at $34.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -6.71. In terms of profitability, ONCO's ROE is -1.05%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ONCO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CRNX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, ONCO is priced at $1.08, while ACAD trades at $21.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.81. In terms of profitability, ONCO's ROE is -1.05%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ONCO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ACAD's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, ONCO is priced at $1.08, while TNGX trades at $31.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas TNGX's P/E ratio is -37.28. In terms of profitability, ONCO's ROE is -1.05%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, ONCO is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TNGX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, ONCO is priced at $1.08, while NAMS trades at $30.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -17.08. In terms of profitability, ONCO's ROE is -1.05%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ONCO is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check NAMS's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ONCO is priced at $1.08, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ONCO's ROE is -1.05%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ONCO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SWTX's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, DNLI has a market cap of 3.4B. Regarding current trading prices, ONCO is priced at $1.08, while DNLI trades at $22.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -7.52. In terms of profitability, ONCO's ROE is -1.05%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ONCO is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check DNLI's competition here

ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ONCO stands at 347.4K. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, ONCO is priced at $1.08, while DNTH trades at $81.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ONCO currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -19.40. In terms of profitability, ONCO's ROE is -1.05%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ONCO is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check DNTH's competition here